A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects with Chronic Non-Malignant Pain.

Primary objectives: To evaluate the efficacy, safety, and tolerability of oral MOA-728 given daily in a population of subjects with chronic, non-malignant pain who have opioid-induced bowel dysfunction. Primary endpoints: The change from baseline in the number of spontaneous bowel movements (SBMs) per week during the double-blind treatment period.